{"id":17299,"date":"2026-06-08T13:56:00","date_gmt":"2026-06-08T11:56:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=a670ed2ff20f07ccecee14e07b403c95"},"modified":"2026-06-08T13:56:00","modified_gmt":"2026-06-08T11:56:00","slug":"diabetologys-breakthrough-clinical-data-from-oraglutide-oral-glp-1","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=17299","title":{"rendered":"Diabetology\u2019s Breakthrough Clinical Data From Oraglutide\u2122 Oral GLP-1"},"content":{"rendered":"<p class=\"bwalignc\">\nOraglutide\u2122 Once Weekly, Low Dose, Low side-effect, Oral GLP-1<\/p><p class=\"bwalignc\">\nGlucose and Insulin Response Over 6 days:<\/p><p class=\"bwalignc\">\nClinical Data Posted at World ADA Diabetes &amp; Obesity Conference<\/p><p>NEW ORLEANS--(BUSINESS WIRE)--Diabetology Limited (Jersey) poster presentation (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdiabetology.co.uk%2Fada-poster&amp;esheet=54549179&amp;newsitemid=20260607631271&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdiabetology.co.uk%2Fada-poster&amp;index=1&amp;md5=9065e02a5ad4b160eec57c270ae1ee97\" rel=\"nofollow\" shape=\"rect\">https:\/\/diabetology.co.uk\/ada-poster<\/a>) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide\u2122 \u2014 small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess\u2122 delivery technology.<\/p><p>\nKEY HIGHLIGHTS<\/p><ul class=\"bwlistdisc\">\n<li>\n<b>6-day glucose control: <\/b>A single 4 mg oral dose of Oraglutide\u2122 produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study.<\/li>\n<li>\n<b>28% increase in insulin secretion: <\/b>Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) &amp; 28% Day 1 (p = 0.025).<\/li>\n<li>\n<b>Novel intestinal depot effect: <\/b>Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding.<\/li>\n<li>\n<b>No nausea or side effects observed: <\/b>No adverse events observed across the 8-subject cohort over one week, consistent with targeting vagal afferent mechanisms that avoids peak off target outer circulation exposures.<\/li>\n<li>\n<b>Dose &gt;6x lower than Rybelsus: <\/b>Biopotency at least six-fold greater than Rybelsus (R2) opens the door to Oraglutide\u2122 low dose, long acting and Satietyde\u2122 microdose maintenance &amp; rebound prevention formulations<\/li>\n<li>\n<b>Circulating Blood Levels<\/b> sufficient to trigger pancreatic GLP-1 receptors observed to Day 4<\/li>\n<li>\n<b>Platform patent cover to 2044: <\/b>Diabetology's licensed Axcess\u2122 formulation technology is protected by patents and applications extending to 2044.<\/li>\n<\/ul><p>\nOraglutide\u2019s\u2122 possibility of optimal compliance from the convenience of a once weekly oral capsule follows the well-established once weekly GLP-1 injection regimen.<\/p><p>\nThe longer action and lower side effect profile emerges from the considerably lower oral dosing and more physiological pathway of delivery via the intestine wall. This is where most GLP-1 is naturally produced and vagal nerve receptors exist to trigger satiety via the brain. These advantages could significantly reduce overall costs of therapy, allow less dropouts and side-effects and opens the possibility of Satietyde\u2122 microdosing to reduce rebound effects following obesity treatments.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nContact Details: Diabetology Limited\n<br\/>Website: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdiabetology.co.uk&amp;esheet=54549179&amp;newsitemid=20260607631271&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdiabetology.co.uk&amp;index=2&amp;md5=fade77717e7e39d6c370655c27ebfccd\" rel=\"nofollow\" shape=\"rect\">https:\/\/diabetology.co.uk<\/a><br\/>Email: <a  href=\"mailto:media@diabetology.co.uk\" rel=\"nofollow\" shape=\"rect\">media@diabetology.co.uk<\/a><br\/>Dr Roger New co-founder CSO (Chief Scientific Officer) UK : +44 (0) 7818 068012\n<br\/>Glen Travers co-founder CEO +44 (0) 7785308176\n<br\/>Gary Walton CFO Oceania: +61 (0) 419425205\n<br\/>Sukumar R India: +91 (0) 7738385489<\/p>","protected":false},"excerpt":{"rendered":"<p>Oraglutide\u2122 Once Weekly, Low Dose, Low side-effect, Oral GLP-1<br \/>\nGlucose and Insulin Response Over 6 days:<br \/>\nClinical Data Posted at World ADA Diabetes &amp; Obesity ConferenceNEW ORLEANS&#8211;(BUSINESS WIRE)&#8211;Diabetology Limited (Jersey) poster presentation &#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-17299","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17299"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17299\/revisions"}],"predecessor-version":[{"id":17300,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17299\/revisions\/17300"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}